ESHAP is an active regimen for relapsing Hodgkin's disease
Open Access
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 10 (5) , 593-595
- https://doi.org/10.1023/a:1026454831340
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s diseaseAnnals of Oncology, 1995
- Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.Journal of Clinical Oncology, 1995
- ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.Journal of Clinical Oncology, 1994
- Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy [see comments]Blood, 1994
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- Hodgkin's DiseaseNew England Journal of Medicine, 1993
- Risk classification as the basis for clinical staging of diffuse large- cell lymphoma derived from 10-year survival dataBlood, 1989
- MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.Journal of Clinical Oncology, 1987